Best of 2023 in Prostate Cancer and Prostatic Diseases.
作者信息
De Nunzio Cosimo, Lombardo Riccardo
机构信息
Department of Urology, Sapienza University of Rome, Rome, Italy.
出版信息
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):165-167. doi: 10.1038/s41391-024-00790-7. Epub 2024 Jan 23.
PMID:38263282
Abstract
摘要
相似文献
1
Best of 2023 in Prostate Cancer and Prostatic Diseases.
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):165-167. doi: 10.1038/s41391-024-00790-7. Epub 2024 Jan 23.
2
Atypical intraepithelial lesions of the prostate gland.
Am J Clin Pathol. 1991 Nov;96(5):561-3. doi: 10.1093/ajcp/96.5.561.
3
[Clinical significance of prostatic cytology and its diagnostic possibilities].
MMW Munch Med Wochenschr. 1974 Jan 4;116(1):15-8.
4
Imaging of the prostate by ultrasound.
J Urol. 1984 Aug;132(2):217-24. doi: 10.1016/s0022-5347(17)49571-1.
5
MR imaging of the prostate and seminal vesicles.
Magn Reson Imaging Clin N Am. 1996 Aug;4(3):497-518.
6
Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities.
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):197-198. doi: 10.1038/s41391-019-0193-7. Epub 2019 Dec 6.
7
Prostatic stromal neoplasms: differential diagnosis of cystic and solid prostatic and periprostatic masses.
AJR Am J Roentgenol. 2013 Jun;200(6):W571-80. doi: 10.2214/AJR.12.9741.
8
A symposium on the surgical pathology of the prostate.
Pathol Annu. 1990;25 Pt 2:109-58.
9
Atypical epithelial hyperplasia or carcinoma of prostate gland: the surgical pathologist at an impasse?
Urology. 1974 Dec;4(6):758-60. doi: 10.1016/0090-4295(74)90267-2.
10
Fine-needle aspiration biopsy of the prostate.
Pathol Annu. 1991;26 Pt 2:89-108.
本文引用的文献
1
The impact of race on survival in metastatic prostate cancer: a systematic literature review.
Prostate Cancer Prostatic Dis. 2023 Sep;26(3):461-474. doi: 10.1038/s41391-023-00710-1. Epub 2023 Aug 17.
2
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):113-118. doi: 10.1038/s41391-022-00561-2. Epub 2022 Jun 10.
3
The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):576-582. doi: 10.1038/s41391-022-00548-z. Epub 2022 May 31.
4
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):431-443. doi: 10.1038/s41391-022-00537-2. Epub 2022 Apr 14.
5
Racial disparities in treatment delay among younger men with prostate cancer.
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):590-592. doi: 10.1038/s41391-021-00479-1. Epub 2022 Feb 21.
6
Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy-implications on clinically-significant prostate cancer detection and relevance to focal therapy planning.
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):720-726. doi: 10.1038/s41391-021-00485-3. Epub 2022 Jan 14.
Zotero 插件